Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.1
3.7
Journals
Pathogens
Special Issues
Gastrointestinal Pathogens in Inflammatory Bowel Disease
share announcement

Gastrointestinal Pathogens in Inflammatory Bowel Disease

A special issue of Pathogens (ISSN 2076-0817).

Deadline for manuscript submissions: 1 July 2024 | Viewed by 4504

Special Issue Editors

Prof. Dr. Daniela Dobru

E-Mail Website
Guest Editor
Gastroenterology Department, Mures County Clinical Hospital, University of Medicine, Pharmacy, Sciences and Technology “George Emil Palade” Târgu Mureș, Târgu Mureș 540136, Romania
Interests: inflammatory bowel disease; colonic polyps; gastric atrophy
Dr. Boeriu Alina

E-Mail
Guest Editor
Gastroenterology Department, Mures County Clinical Hospital, University of Medicine, Pharmacy, Sciences and Technology “George Emil Palade” Târgu Mureș, Târgu Mureș 540136, Romania
Interests: hepatology; inflammatory bowel disease; colon cancer
Dr. Roman Adina

E-Mail Website
Guest Editor
Gastroenterology Department, Mures County Clinical Hospital; University of Medicine, Pharmacy, Sciences and Technology “George Emil Palade” Târgu Mureș, Târgu Mureș 540136, Romania
Interests: inflammatory bowel disease; hepatology; gut microbiota

Special Issue Information

Dear Colleagues,

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are chronic disorders with recurrent symptoms and potential severe complications, resulting in a significant burden on healthcare systems. The role of intestinal microbiota in IBD pathogenesis and disease activity represents a field of great clinical interest and has been intensively studied, and new therapeutic opportunities have emerged. It is important to analyze how microbial groups may be involved in the pathogenic mechanism of IBD, in the negative course of the disease, in the development of complications, or in different responses to therapy. 

The aim of this Special Issue, “Gastrointestinal Pathogens in Inflammatory Bowel Disease”, is to present current knowledge in the field relating to the complex mechanisms that promote intestinal inflammation, the impact  of the modulation of gut microbiota in IBD course, therapeutic strategies, vaccine strategies, as well as associated pathogens and their specific management. We invite authors to contribute to this Special Issue with original research articles, short communications, and review articles.

Potential topics include, but are not limited to:

  • Gut microbiota and IBD;
  • Clostridium difficile infection in IBD;
  • Anti-TNF-alpha treatment and gut microbiota;
  • Fecal transplantation and its role in gut microbiota;
  • Risk of infections secondary to IBD therapy;
  • Antibiotic therapy in IBD;
  • Nutritional therapies, prebiotics, probiotics, and synbiotics in IBD;
  • Vaccine strategies in IBD;
  • Management of IBD patients with COVID-19.

Prof. Dr. Daniela Dobru
Dr. Boeriu Alina
Dr. Roman Adina
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

16 pages, 699 KiB  
Review
The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases
by Alina Boeriu, Adina Roman, Crina Fofiu and Daniela Dobru
Pathogens 2022, 11(7), 819; https://doi.org/10.3390/pathogens11070819 - 21 Jul 2022
Cited by 12 | Viewed by 2822
Abstract
Clostridioides difficile (C. difficile) represents a major health burden with substantial economic and clinical impact. Patients with inflammatory bowel diseases (IBD) were identified as a risk category for Clostridioides difficile infection (CDI). In addition to traditional risk factors for C. difficile [...] Read more.
Clostridioides difficile (C. difficile) represents a major health burden with substantial economic and clinical impact. Patients with inflammatory bowel diseases (IBD) were identified as a risk category for Clostridioides difficile infection (CDI). In addition to traditional risk factors for C. difficile acquisition, IBD-specific risk factors such as immunosuppression, severity and extension of the inflammatory disease were identified. C. difficile virulence factors, represented by both toxins A and B, induce the damage of the intestinal mucosa and vascular changes, and promote the inflammatory host response. Given the potential life-threatening complications, early diagnostic and therapeutic interventions are required. The screening for CDI is recommended in IBD exacerbations, and the diagnostic algorithm consists of clinical evaluation, enzyme immunoassays (EIAs) or nucleic acid amplification tests (NAATs). An increased length of hospitalization, increased colectomy rate and mortality are the consequences of concurrent CDI in IBD patients. Selection of CD strains of higher virulence, antibiotic resistance, and the increasing rate of recurrent infections make the management of CDI in IBD more challenging. An individualized therapeutic approach is recommended to control CDI as well as IBD flare. Novel therapeutic strategies have been developed in recent years in order to manage severe, refractory or recurrent CDI. In this article, we aim to review the current evidence in the field of CDI in patients with underlying IBD, pointing to pathogenic mechanisms, risk factors for infection, diagnostic steps, clinical impact and outcomes, and specific management. Full article
(This article belongs to the Special Issue Gastrointestinal Pathogens in Inflammatory Bowel Disease)
►▼ Show Figures

Figure 1

Other

Jump to: Review

14 pages, 673 KiB  
Systematic Review
Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease
by Adrian Boicean, Dan Bratu, Sorin Radu Fleaca, Gligor Vasile, Leeb Shelly, Sabrina Birsan, Ciprian Bacila and Adrian Hasegan
Pathogens 2023, 12(9), 1149; https://doi.org/10.3390/pathogens12091149 - 09 Sep 2023
Cited by 1 | Viewed by 1288
Abstract
This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in [...] Read more.
This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in IBD patients. Considering the similarities in immunomodulation and dysbiosis between IBD and TB, this review hypothesizes that FMT may offer therapeutic benefits as an adjunct therapy in TB. Methods: We conducted a systematic review of the existing literature on FMT in IBD and TB, highlighting the mechanisms and potential implications of FMT in the therapeutic management of both conditions. The findings contribute to understanding FMT’s potential role in TB treatment and underscore the necessity for future research in this direction to fully leverage its clinical applications. Conclusion: The integration of FMT into the comprehensive management of TB could potentially enhance treatment outcomes, reduce drug resistance, and mitigate the side effects of conventional therapies. Future research endeavors should focus on well-designed clinical trials to develop guidelines concerning the safety and short- and long-term benefits of FMT in TB patients, as well as to assess potential risks. Full article
(This article belongs to the Special Issue Gastrointestinal Pathogens in Inflammatory Bowel Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: SARS-CoV-2 infection: an enteric pathogen in Inflammatory Bowel Disease - a systematic review
Author: Roman
Highlights: - Analysis of clinical, paraclinical characteristics of SARS-CoV-2 infection in IBD patients - Analysis of therapeutic management of SARS-CoV-2 infection in IBD patients - Analysis of risk factors in IBD patients for developing severe COVID-19 - Impact of SARS-COV-2 infection over immunological and mucosal function in IBD patients

Back to TopTop